A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes
Latest Information Update: 04 Jun 2026
At a glance
- Drugs ENT-03 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Calzada; Enterin
Most Recent Events
- 01 Jun 2026 The protocol has been amended to modifications in primary safety endpoints with time frames.
- 01 Jun 2026 Status changed from active, no longer recruiting to completed.
- 25 Jun 2025 Top line result data presented in the Metabolics Pharma Media Release.